Last update at 2025-03-14T20:00:00Z
LeMaitre to Participate at Upcoming Investor Conferences in March
Mon 03 Mar 25, 10:06 PMLeMaitre Q4 2024 Financial Results
Thu 27 Feb 25, 09:05 PMLeMaitre Will Announce Fourth Quarter 2024 Earnings Results February 27, 2025
Mon 27 Jan 25, 08:15 PMBreakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
Income before tax | 27.49M | 34.29M | 27.36M | 21.68M | 28.44M |
Minority interest | - | - | - | - | - |
Net income | 20.64M | 26.91M | 21.22M | 17.93M | 22.94M |
Selling general administrative | 28.75M | 25.50M | 22.50M | 19.05M | 17.69M |
Selling and marketing expenses | 32.92M | 27.66M | 23.70M | 30.34M | 27.32M |
Gross profit | 104.90M | 101.38M | 84.62M | 79.85M | 73.94M |
Reconciled depreciation | 9.43M | 11.07M | 8.39M | 5.42M | 4.32M |
Ebit | 21.16M | 25.55M | 19.80M | 15.77M | 8.94M |
Ebitda | 30.60M | 36.62M | 28.20M | 21.18M | 13.26M |
Depreciation and amortization | 9.43M | 11.07M | 8.39M | 5.42M | 4.32M |
Non operating income net other | 0.66M | 0.08M | -0.12200M | 0.50M | 0.24M |
Operating income | 21.16M | 25.55M | 19.80M | 15.77M | 28.21M |
Other operating expenses | 131.72M | 118.00M | 101.05M | 96.05M | 84.83M |
Interest expense | 0.99M | 2.22M | 1.31M | 5.91M | 0.00200M |
Tax provision | 6.85M | 7.38M | 6.14M | 3.75M | 5.50M |
Interest income | 0.99M | 0.20M | 0.21M | 0.70M | 0.63M |
Net interest income | 0.99M | -2.02200M | -1.31000M | 0.70M | 0.63M |
Extraordinary items | - | - | - | - | 0.40M |
Non recurring | 3.11M | - | -0.47000M | - | - |
Other items | - | - | - | - | - |
Income tax expense | 6.85M | 7.38M | 6.14M | 3.75M | 5.50M |
Total revenue | 161.65M | 154.42M | 129.37M | 117.23M | 105.57M |
Total operating expenses | 74.96M | 64.96M | 56.30M | 58.67M | 53.20M |
Cost of revenue | 56.76M | 53.04M | 44.75M | 37.38M | 31.63M |
Total other income expense net | 6.33M | 8.73M | 7.55M | 5.91M | 7.71M |
Discontinued operations | - | - | - | - | - |
Net income from continuing ops | 20.64M | 26.91M | 21.22M | 17.93M | 22.94M |
Net income applicable to common shares | 20.64M | 26.91M | 21.22M | 17.93M | 22.94M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Total assets | 346.78M | 310.48M | 292.80M | 252.81M | 188.34M |
Intangible assets | 41.71M | 46.53M | 52.71M | 58.91M | 23.19M |
Earning assets | - | - | - | - | - |
Other current assets | 6.38M | 6.73M | 4.19M | 2.62M | 3.31M |
Total liab | 48.88M | 42.27M | 38.65M | 80.24M | 40.20M |
Total stockholder equity | 297.90M | 268.20M | 254.15M | 172.57M | 148.14M |
Deferred long term liab | - | - | 0.07M | 0.70M | 1.18M |
Other current liab | 23.28M | 20.54M | 1.27M | 0.77M | 2.48M |
Common stock | 0.24M | 0.24M | 0.23M | 0.22M | 0.22M |
Capital stock | 0.24M | 0.24M | 0.23M | 0.22M | 0.22M |
Retained earnings | 115.43M | 97.77M | 88.12M | 70.55M | 57.03M |
Other liab | - | 2.24M | 2.77M | 4.77M | 5.39M |
Good will | 65.94M | 65.94M | 65.94M | 65.94M | 41.66M |
Other assets | - | 2.74M | 2.13M | 18.45M | 1.34M |
Cash | 24.27M | 19.13M | 13.86M | 26.76M | 11.79M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 29.88M | 25.33M | 21.81M | 25.14M | 20.86M |
Current deferred revenue | 0.39M | - | 16.33M | 17.52M | 14.02M |
Net debt | -5.17400M | -2.53800M | 2.08M | 28.01M | 3.93M |
Short term debt | 2.47M | 1.89M | 1.87M | 4.45M | 1.76M |
Short long term debt | - | - | - | 2.50M | - |
Short long term debt total | 19.09M | 16.60M | 15.94M | 54.78M | 15.71M |
Other stockholder equity | 186.86M | 176.22M | 169.23M | 103.32M | 94.90M |
Property plant equipment | - | 17.90M | 32.13M | 15.04M | 14.85M |
Total current assets | 188.85M | 161.73M | 139.88M | 94.26M | 92.09M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | 155.73M | 135.50M | 113.67M | 108.19M |
Short term investments | 80.81M | 63.56M | 56.10M | 0.21M | 20.89M |
Net receivables | 25.06M | 22.04M | 19.63M | 19.55M | 16.57M |
Long term debt | - | - | - | 35.53M | - |
Inventory | 52.33M | 50.27M | 46.10M | 45.12M | 39.53M |
Accounts payable | 3.73M | 2.90M | 2.34M | 2.39M | 2.60M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | -4.62500M | -6.03100M | -3.43500M | -1.52500M | -4.00700M |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | 0.24M | 0.23M | 0.22M | 0.22M |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | 97.77M | 88.12M | 70.55M | 57.03M |
Treasury stock | - | -13.04600M | -12.40400M | -11.60200M | -11.03200M |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 9.49M | 0.99M | 0.57M | 0.91M | 0.26M |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 157.93M | 148.74M | 152.92M | 158.55M | 96.25M |
Capital lease obligations | 19.09M | 16.60M | 15.94M | 16.75M | 15.71M |
Long term debt total | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
Investments | -22.85600M | -8.00000M | -56.19400M | 20.70M | 0.90M |
Change to liabilities | - | 0.65M | -1.73400M | 4.32M | -0.59600M |
Total cashflows from investing activities | - | -10.37100M | -61.07600M | -52.89100M | -24.10000M |
Net borrowings | - | - | -39.00000M | 37.25M | 39.00M |
Total cash from financing activities | -7.13100M | -9.23400M | 13.70M | 32.16M | -4.62200M |
Change to operating activities | - | -3.09600M | -1.92700M | 0.09M | -0.65400M |
Net income | 30.11M | 20.64M | 26.91M | 21.22M | 17.93M |
Change in cash | 5.13M | 5.28M | -12.90900M | 14.98M | -14.53200M |
Begin period cash flow | 19.13M | 13.86M | 26.76M | 11.79M | 26.32M |
End period cash flow | 24.27M | 19.13M | 13.86M | 26.76M | 11.79M |
Total cash from operating activities | 36.75M | 25.38M | 35.10M | 34.80M | 14.18M |
Issuance of capital stock | 6.86M | 3.47M | 63.24M | 5.97M | 4.86M |
Depreciation | 9.52M | 9.43M | 11.07M | 8.39M | 5.42M |
Other cashflows from investing activities | - | 0.86M | - | -70.60400M | -21.24000M |
Dividends paid | 12.45M | 10.99M | 9.34M | 7.70M | 6.74M |
Change to inventory | -9.79400M | -7.41800M | -5.48500M | -2.60900M | -11.33500M |
Change to account receivables | -3.13500M | -3.53300M | -0.81800M | -0.93900M | -1.30100M |
Sale purchase of stock | -0.85300M | -0.64200M | -0.80200M | -0.57000M | -0.68300M |
Other cashflows from financing activities | 7.13M | -1.07000M | -0.40100M | 60.45M | -2.05900M |
Change to netincome | - | 8.71M | 7.09M | 4.32M | 4.71M |
Capital expenditures | 7.26M | 3.23M | 4.88M | 2.98M | 3.76M |
Change receivables | - | -3.53300M | -0.81800M | -0.93900M | -1.30100M |
Cash flows other operating | - | -10.51400M | -7.41200M | -2.52000M | -11.98900M |
Exchange rate changes | - | - | - | - | 0.01M |
Cash and cash equivalents changes | - | 5.77M | -12.27200M | 14.06M | -14.53200M |
Change in working capital | -11.25400M | -13.40200M | -9.96400M | 0.86M | -13.88600M |
Stock based compensation | 5.32M | 4.17M | 3.48M | 3.02M | 2.64M |
Other non cash items | 2.28M | 4.72M | 3.53M | 1.63M | 1.25M |
Free cash flow | 29.49M | 22.15M | 30.22M | 31.82M | 10.42M |
Sector: Healthcare Industry: Medical Instruments & Supplies
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
LMAT LeMaitre Vascular Inc |
3.09 3.92% | 81.91 | 52.74 | 38.76 | 7.46 | 4.85 | 7.02 | 27.72 |
ISRG Intuitive Surgical Inc |
7.66 1.61% | 484.44 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
ESLOY Essilor International SA |
0.38 0.27% | 143.02 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
ESLOF EssilorLuxottica Société anonyme |
-0.19 0.07% | 284.00 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
BDX Becton Dickinson and Company |
3.19 1.43% | 225.98 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
63 Second Avenue, Burlington, MA, United States, 01803
Name | Title | Year Born |
---|---|---|
Mr. George W. LeMaitre | Chairman & CEO | 1965 |
Mr. David B. Roberts | Pres & Director | 1964 |
Mr. Joseph P. Pellegrino Jr. | CFO, Treasurer, Sec. & Director | 1965 |
Mr. Trent G. Kamke | Sr. VP of Operations | 1971 |
Dr. George D. LeMaitre | Founder and Chairman of Scientific Advisory Board | 1934 |
Ms. Laurie A. Churchill | Sr. VP & Gen. Counsel | 1971 |
Ms. Kimberly L. Cieslak | VP of Marketing | 1973 |
Mr. Daniel J. Mumford | Director of HR | 1982 |
Mr. Andrew Hodgkinson | Sr. VP of Clinical, Regulatory & Quality Affairs | 1976 |
Mr. Stephane Maier | Sr. VP of EMEA Operations | 1976 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.